loan agreement

The company ended 2017 with $10 million in cash and cash equivalents, and raised $40 million in a public offering in January.

The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.

The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.

Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.

The loan can be funded at Invitae's option during the second quarter of 2018 and will provide flexibility as the firm grows its genome network.

The firm said it expects to finance the construction of a clinical lab and related facilities, as well as additional development of a 46-acre campus.

The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.

Brooks also said it has signed a seven-year, $200 million senior term loan agreement with a group of institutional investors.

The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.

The firm said it may use the loans to finance its $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics.